OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively, OWCP, OWC Pharmaceuticals Research Corp, "One World Cannabis ", "OWC" or "the Company") for the development of cannabinoid-based therapies targeting a variety of different medical conditions. The Company s research division is focused on pursuing clinical trials, evaluating the effectiveness of cannabinoids in the treatment of these various medical conditions. This presentation outlines the specific needs and the special opportunities that OWC believes exist in the medical cannabis market together with OWCP s research and development activity to date and the potential target markets for OWC s present and planned products. This presentation also details the Company s business strategy and financial information operation based on certain assumptions, market data, and OWC s opinions. This presentation has been developed in a reasonable and rational manner to reflect OWC s plan setting forth a defined time schedule based partly on known information, and partly on assumptions and forecasts of OWC. However, as with all business plans, its anticipated results are based on information available at the time of preparation, relying on that information s accuracy and reliability, and also based on the specific assumptions made. Changes in the economical and regulatory factors, among others, as well as additional information or various other events, can change the assumptions as well as the results. This presentation itself does not guarantee its partial or full execution. Therefore, it is possible that this business plan will not be fully implemented and executed as planned. Confidential information All information contained herein contains copyrighted information that is proprietary, privileged or confidential. It is intended only for the purpose specified and directed to the recipients specifically identified by the company. Any unauthorized review, disclosure, reproduction, distribution, copying of, or reliance upon this document and any included exhibits is strictly prohibited.
One World Cannabis Ltd. One World Cannabis Ltd. was set up in July 2014 in Israel as a Wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB:OWCP). The state of Israel supports cannabis study and scientific research since the 1960s in renown academic and research hospitals. The Medical Cannabis Unit under the Health Minister Office is operating in Israel since 2003
Vision OWC Pharmaceutical aims to become a leader in creating new cannabis-related treatments and devices targeting a variety of diseases and medical conditions, by identifying unique formulation and efficient delivery systems. We are determined to bring the safe messages of clinically tested cannabis treatments by aiding regulators and business groups worldwide through our international division for regulatory affairs
Mission R&D Division: All our studies are following an approved clinical procedures by IRB protocols conducted in Israeli hospitals facilities. Each new product targets a specific disease or medical conditions, with a particular focus on identifying unique formulation and efficient delivery systems to optimize the bio-availability of each dosage Consulting Division: Supporting and aiding organizations and states which are on the way to implement MMJ program and are looking to adopt the Israeli MMJ Methodology which includes patients treatments, recommended daily dosage, manufacturing standards, education programs, knowledge transfer to physicians and more.
What is Medical Cannabis? Tetrahydrocannabinol (THC) Psychoactive component of cannabis. Medically used for the treatment of epilepsy and other conditions. Isolated in 1964 by Israeli researchers at the Hebrew University in Jerusalem. Cannabidiol (CBD) Non-psychoactive component of cannabis. Medical uses as an anti-inflammatory agent with numerous beneficial qualities
Medical Cannabis Market USATODAY: ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm says that by 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion. http://www.usatoday.com/story/news/2016/03/20/legal-marijuanasales-forecast-hit-23b-4-years/82047272/
OWCP Competitive Edge Based in Israel: Cannabis research is supported by the Israeli government, one of the few countries worldwide to approve clinical studies with cannabis Dr. Med. Yehuda Baruch: leading our two divisions as the Chief scientist officer and regulatory affairs, Dr. Baruch, a world renowned Psychiatrist, founded, implemented and Headed the Israeli Medical Cannabis Unit under the Minister of Health for over 10 years.
OWCP Products
Cannabis Based Products IP-owned developed of new innovative and tested delivery systems. Delivery systems Ready : Sublingual Soluble tablet: replacement of smoking, pain treatment. more than 10 million potential patients in the approved MMJ states. Topical crème: Treatment for different skin diseases starting with tested psoriasis. ~8 Million Psoriasis patients US & Canada (2.5% of population) Fixed and controlled dosage Quality controlled Waiting for safety and clinical results
OWCP Active Studies
Multiple Myeloma (a cancer of plasma cells) Designed to be an Orphan Disease study approved by the FDA In-vitro study completed 06/2015 Cannabis kills the MM cancer cells Pre-clinic study on mice completed 12/2015 calibration phase for dosage, found most effective ratio of active cannabinoids THC/CBD In-vitro study for a combination of 4 approved drugs with cannabis completed 05/2016 promising results Pre-clinic study for the most effective combination on mice with new cannabis extracts. On-going testing. SUBJECT TO ACHIEVING SCIENTIFIC MILESTONES THE COMPANY WILL SUBMITT AN APPLICATION WITH THE FDA FOR AN ORPHAN DISEASE DESIGNATION
Psoriasis (Skin Disease) Pharma-grade challenge tests successfully completed 05/2016 Active Safety study at the biggest academic hospital in Israel, under approved IRB (Helsinki) protocol. In-vitro psoriasis Pre Clinical efficacy study of the topical crème - completed - Up to 70% improvement with inflammation markers directly related to Psoraisis IP owned by OWCP EXPECTED MARKET READINESS : Q3/2017
Roadmap Utilizing the existing products for new medical indications Tablets for pain relief: PTSD, Fibromyalgia and Pain (Migraine) Crème for skin diseases: Psoriasis firs with possible Acne, Basal cell carcinoma, Atopic dermatitis and more Developing another new delivery system
Strategic Alliances
MICHEPRO Ltd. Michepro A European distribution company; Signed a Joint-Venture agreement, 75% (OWCP) 25% (MICHEPRO Ltd); Aim: to set up a European entity to promote, manufacture and sell OWCP products in Europe
Accomplishments (since 7/2014): April 2017 Clinical studies: Delivery system: Patents: Two active studies Three systems (Two ready - tablets; cream; One in development) Eight patents
Corporate & Financial Details A Delaware corporation, fully SEC reporting company trading in the QB Tier of the OTC market : OWCP:QB Debt free Sufficient funds to complete current 2017 operating and BP Authorized Capital :500,000,000 Outstanding shares: 144,719,287 (31 March 2017) Float: 125,000,000 (31 March 2017)
Management Team OWCP management is composed of a highly experienced team of experts in various areas of the medical cannabis, clinical research, healthcare management, international business and financial markets. Mr. Mordechai Bignitz Chairman; CEO of OWC Pharmaceuticals Research Corp. Veteran businessman with 35 years of experience with executive leadership in large international corporations, Including senior positions with Pharma and Biotech companies and the chairman of the biggest investment fund in Israel for 9 Yrs. Dr. Med. Yehuda Baruch CSO, Director of Research and Regulatory Affairs. Former CEO of Abarbanel Mental Health Center in Bat-Yam. The founder of the Israeli Medical Cannabis program and its director for 10 years Mr. Alon Sinai Chief Operating Officer and Interim Chief Executive Officer Retired Lieutenant-Colonel from the IDF Medical Corps. Was responsible for supervising and developing emergency medical facilities Mr. Shmuel De-Saban, CPA CFO, OWCP and One World Cannabis Ltd 19
Advisory Team The Advisory Team, which is made up of industry thought-leaders and experts, evaluates the Medical Cannabis market (clinical research; healthcare management; financial data), and provides the Management Team strategic and tactical advice, as well as feedback from an industry and community perspective. Mr. Jeffrey Friedland Advisory Board Member. The author of "Marijuana: The World's Most Misunderstood Plant." He is a regular speaker on the cannabis industry and has been featured or quoted in numerous publications. Mr. Friedland has investments and business involvements in the cannabis industry globally. Dr. Sharon Rozenblat VPSenior Advisor To Scientific Advisory Board Dr. Rozenblat will be tasked with overseeing the completion of the pre-clinical safety studies on the Company s treatment for psoriasis. Dr. Rozenblat will also steer the Company s efforts to commercialize OWC s cannabis-based formulations and delivery mechanisms. Ms. Miri Sani, MSc Eng. Advisory board member. Ms. Sani is the CEO and owner of Shefa Amirim Ltd, which provides regulatory affairs and clinical consultation services for early stage start-ups in various medical fields. Ms. Sani will advise the company s management on the transition of the in-house innovative developed cannabinoids products and delivery systems, to full industrial production, 20
For further information: Visit our website - www.owcpharma.com Or contact: Mr. Mordechai Bignitz, Chairman & CEO mordechai.bignitz@owcpharma.com Dr. Yehuda Baruch, CSO yehuda.baruch@owcpharma.com